Northern Trust Corp Boosts Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Northern Trust Corp lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 26.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,689,098 shares of the company’s stock after acquiring an additional 991,022 shares during the quarter. Northern Trust Corp owned 0.10% of Novo Nordisk A/S worth $403,356,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Center for Financial Planning Inc. boosted its stake in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after acquiring an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL increased its holdings in shares of Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock valued at $27,000 after purchasing an additional 300 shares during the period. Transce3nd LLC acquired a new position in Novo Nordisk A/S during the fourth quarter worth $33,000. Kelly Lawrence W & Associates Inc. CA acquired a new position in Novo Nordisk A/S during the fourth quarter worth $39,000. Finally, Albion Financial Group UT grew its holdings in Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after acquiring an additional 278 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on NVO. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BMO Capital Markets reiterated a “market perform” rating and set a $64.00 target price (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Dbs Bank downgraded Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. Guggenheim lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Two analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $135.00.

Novo Nordisk A/S Stock Up 4.0 %

Shares of Novo Nordisk A/S stock opened at $65.12 on Wednesday. The stock has a market capitalization of $292.23 billion, a price-to-earnings ratio of 19.79, a PEG ratio of 0.90 and a beta of 0.61. The business’s 50 day simple moving average is $72.84 and its 200-day simple moving average is $88.85. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were issued a $0.7874 dividend. The ex-dividend date of this dividend was Monday, March 31st. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.54%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.